| 000 | 03726nam a22003375i 4500 | ||
|---|---|---|---|
| 999 |
_c399279 _d399279 |
||
| 001 | 399279 | ||
| 003 | ES-MaUEC | ||
| 005 | 20240518191240.0 | ||
| 006 | a|||| o|||| 00| 0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 230630s2023 si | o |||| 0|eng d | ||
| 020 | _a9789819915293 | ||
| 024 | 7 |
_a10.1007/978-981-99-1529-3 _2doi |
|
| 040 |
_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC |
||
| 050 | 4 |
_aRC270.8 _b2023 EB |
|
| 245 | 0 | 0 |
_aOncology : _bGenomics, Precision Medicine and Therapeutic Targets _cedited by Hardeep Singh Tuli, Mükerrem Betül Yerer Aycan |
| 250 | _a1st ed. 2023 | ||
| 264 | 1 |
_aSingapore _bSpringer Nature Singapore _c2023 |
|
| 300 | _a1 recurso en línea | ||
| 336 |
_atexto _btxt _2rdacontent |
||
| 337 |
_aelectrónico _bc _2rdamedia |
||
| 338 |
_arecurso electrónico _bcr _2rdacarrier |
||
| 505 | 0 | _aChapter 1 Evolution of translational cancer therapeutics -- Chapter 2 Oncology: Way forward from clinical and molecular diagnosis to treatment -- Chapter 3 Oncogenic genomics alterations in cancer patient -- Chapter 4 Altered mRNA expression profiles in cancer patients -- Chapter 5 microRNAs and long non-coding RNAs as key targets -- Chapter 6 Oncogenic alterations translated into diagnostics -- Chapter 7 Precision medicine in oncology -- Chapter 8 Precision medicine - translation of individualistic treatment in oncology -- Chapter 9Pharmacogenetics and Pharmacogenomics in Precision Medicine -- Chapter 10 Pharmacogenetic factors in pharmacodynamic/pharmacokinetic (PD/PK) modulations of medicines -- Chapter 11 Biomarkers in Precision Medicine in oncology -- Chapter 12 Bioinformatics and biostatistics in Precision Medicine -- Chapter 13 Omics in Precision medicine -- Chapter 14 Translational therapeutic targets : from bench to clinical trials -- Chapter 15 Strength of integartive genomic alterations, precision medicine and therapeutic targets as treatment choice in patient care. | |
| 520 | _aThis book describes translational cancer therapeutics and the way forward from clinical and molecular diagnosis to treatment. In addition, genomics alterations, microRNAs, and long non-coding RNAs translate precision medicine for the individualistic therapy of cancer patients. It describes the involvement of various pharmacogenetic factors in pharmacodynamic/pharmacokinetic (PD/PK) modulations of medicines. Indeed, the role of bioinformatics and biostatistics, considering the extensive data analysis serving precision medicine approaches, has also been entertained in the present book. Therefore, intended book demonstrates the successful medical evidence for the use of precision medicine in the treatment of cancer and its future clinical perspectives. It fills the gaps in cancer biology and precision medicine with its up-to-date content and well-designed chapters. It will serve as a valuable resource for science, medical students, and interdisciplinary researchers. It is a very welcome addition for the scientific community, research centers, and university-industry research collaborators to find out a complete capsular package about cancer drug targets, precision, and personalized medicine (including an introduction to cancer cell signaling, genomic alterations, miRNA targeting, pharmacogenetics, biomarkers, and metabolomics in precision medicine, etc.) at a single platform. | ||
| 988 | _aSpringer_BiomedLife_2023 | ||
| 650 | 7 |
_2embne _9174085 _aCáncer _xTratamiento |
|
| 650 | 7 |
_2embne _9273952 _aCáncer _xAspectos genéticos |
|
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-99-1529-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 942 |
_2lcc _cLE |
||
| 998 |
_b05/2024 _dz _eIG _zSI |
||